Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, Alexander Eggermont et al.|Nature Communications|2017Cited by 201
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaC. Mignard, P. Joly, Aurélie Deschamps Huvier et al.|Journal of Oncology|2018Cited by 82
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM. Kandel, Isabelle Borget, Clara Allayous et al.|European Journal of Cancer|2018Cited by 38
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohortPauline Tétu, Célèste Lebbé, Clara Allayous et al.|European Journal of Cancer|2019Cited by 35
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control studyLéo Plaçais, Célèste Lebbé, Stéphane Dalle et al.|Annals of the Rheumatic Diseases|2022Cited by 34